📰 Radx Tech News
Radx Tech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Radx Tech. Real-time updates on events, politics, business and more.
April 8, 2024
Home Test to Treat program is closing April 16. Patients have limited options for testing and getting treatment with Paxlovid.
December 10, 2021
(The Conversation is an independent and nonprofit source of news, analysis and commentary...
October 19, 2021
Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).
October 14, 2021
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
October 14, 2021
The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
December 16, 2020
“FDA continues to authorize COVID-19 tests that will give more Americans access to greater testing flexibility and options,” FDA Commissioner Stephen M. Hahn said. “The BinaxNOW COVID-19 Ag Home Test will have a significant manufacturing footprint with the potential to support testing for millions of people.” Abbott expects to produce 30 million BinaxNOW at-home tests in the first quarter of 2021 and an additional 90 million in the second quarter. It requires a prescription, unli...
December 16, 2020
“FDA continues to authorize COVID-19 tests that will give more Americans access to greater testing flexibility and options,” FDA Commissioner Stephen M. Hahn said. “The BinaxNOW COVID-19 Ag Home Test will have a significant manufacturing footprint with the potential to support testing for millions of people.” Abbott expects to produce 30 million BinaxNOW at-home tests in the first quarter of 2021 and an additional 90 million in the second quarter. It requires a prescription, unli...